International Journal of Advanced Research in Medicinal Chemistry
Volume 5, Print Issue 2 - 2023, Pg. No. 6-9
Peer Reviewed Journal

Review Article

CRISPR Technology in Drug Discovery: Revolutionizing Target Identification and Therapeutic Development

Prakash Reddy

Student, Smt. Sarojini Ramulamma College of Pharmacy.

INFO

E-mail Id:
drreddyp58@gmail.com

How to cite this article:
Reddy P. CRISPR Technology in Drug Discovery: Revolutionizing Target Identification and Therapeutic Development. *Int J Adv Res Med Chem* 2023; 5(2): 6-9

Date of Submission: 2023-08-15
Date of Acceptance: 2023-09-18

ABSTRACT

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology has emerged as a revolutionary tool in the field of drug discovery, providing researchers with unprecedented precision and efficiency in gene editing. In this article we explore the applications of CRISPR technology in drug discovery, with a focus on target identification and therapeutic development. We delve into the underlying mechanisms of CRISPR, its evolution, and the diverse CRISPR-based methodologies employed in drug discovery pipelines. The paper also addresses the challenges and ethical considerations associated with CRISPR applications in the pharmaceutical industry.

Keywords: CRISPR Technology, Therapeutic Development, Drug Discovery

Introduction

The introduction provides an overview of the historical context of gene editing technologies, leading up to the development of CRISPR. The section also highlights the significance of CRISPR in drug discovery, emphasizing its potential to accelerate the identification of therapeutic targets and streamline the drug development process.

CRISPR Technology

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology represents a revolutionary breakthrough in genetic engineering, providing scientists with an exceptionally precise and efficient tool for editing DNA. Initially discovered as a bacterial defence mechanism against viruses, CRISPR has been adapted for use in diverse organisms, including plants, animals, and humans. The key components of CRISPR include the Cas9 protein and guide RNA (gRNA), which work together to target specific DNA sequences and induce precise modifications.[1] This remarkable technology has far-reaching applications, from correcting genetic mutations associated with diseases to creating genetically modified organisms with desired traits in agriculture. CRISPR's accessibility and versatility have accelerated progress in biomedicine, biotechnology, and agriculture, opening up new possibilities for therapeutic interventions, disease modelling, and sustainable agricultural practices. Despite its tremendous potential, ethical considerations and ongoing research efforts continue to shape the responsible use and further development of CRISPR technology.[2]

The mechanism of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology involves a series of molecular processes that enable precise and targeted editing of DNA. The key components of the CRISPR system are the Cas9 protein and guide RNA (gRNA). Here's an overview of the CRISPR mechanism:

Recognition of Target DNA Sequence

The CRISPR system initially acquires small DNA sequences, known as "spacers," from invading viruses or plasmids and incorporates them into the bacterial genome.

These spacers serve as a molecular memory of past infections and guide the CRISPR system to recognize and defend against specific DNA sequences.[3]

Transcription of CRISPR Array

The CRISPR array, containing the acquired spacers, is transcribed into a long precursor CRISPR RNA (pre-crRNA) molecule.

Processing of pre-crRNA

The pre-crRNA undergoes processing to generate mature CRISPR RNA molecules (crRNAs). Each crRNA corresponds to a specific spacer sequence and serves as a guide for the subsequent steps.

Formation of Cas9-gRNA Complex

The Cas9 protein associates with the crRNA to form the Cas9-gRNA complex.

This complex is now ready to recognize and bind to the target DNA sequence.[4]

Target DNA Recognition and Binding

The crRNA in the Cas9-gRNA complex guides the Cas9 protein to the target DNA sequence by base-pairing with complementary sequences.

The target DNA sequence is typically adjacent to a specific motif known as the Protospacer Adjacent Motif (PAM), which is recognized by the Cas9 protein.

DNA Cleavage

Once the Cas9-gRNA complex binds to the target DNA, the Cas9 protein induces a double-strand break (DSB) at the precise location specified by the guide RNA.

The cellular repair machinery then comes into play to repair the DSB through either non-homologous end joining (NHEJ) or homology-directed repair (HDR).

In NHEJ, the broken DNA ends are rejoined, often introducing small insertions or deletions (indels) that can disrupt the targeted gene's function.[5]

In HDR, an exogenous DNA template can be provided to facilitate precise repair, allowing for the insertion of specific sequences or modifications.

Applications in Target Identification

The identification of suitable targets for CRISPR-Cas editing involves systematic approaches to pinpoint genes or genomic elements that play crucial roles in specific biological processes or diseases. Several methods are employed in CRISPR-Cas target identification:

Genome-Wide CRISPR Screens

- **Loss-of-Function Screens:** Large-scale knockout screens involve systematically disrupting individual genes to observe the resulting phenotypic changes. This helps identify genes essential for specific cellular functions or disease pathways.
- **Gain-of-Function Screens:** These screens involve activating or overexpressing genes to identify those enhancing particular functions or contributing to disease progression.[6]

Bioinformatics and Computational Approaches

Leveraging existing genomic databases, bioinformatics tools help identify potential target genes based on criteria such as expression patterns, pathway analysis, and disease associations. Computational methods enhance the efficiency of target prediction.

Functional Genomics Data Integration

Integrating various functional genomics datasets, including transcriptomics, proteomics, and epigenomics, helps prioritize candidate genes. This holistic approach provides a more comprehensive understanding of gene function.

CRISPR-Interference (CRISPRi) and CRISPR-Activation (CRISPRa)

CRISPRi can be used to selectively repress gene expression, providing a reversible method for assessing the impact of gene downregulation on cellular processes.

CRISPRa, on the other hand, induces targeted gene activation, aiding in the identification of genes that positively regulate specific functions.[7]

Functional Genomic Libraries

Utilizing CRISPR libraries containing guide RNAs (gRNAs) targeting multiple genes allows for the systematic exploration of gene function. Libraries are designed to cover the entire genome or specific gene families.

Cell Type-Specific Approaches

Target identification can benefit from considering the specific cell type or tissue of interest. Cell type-specific CRISPR screens help uncover genes relevant to a particular biological context.

High-Throughput Sequencing

Employing high-throughput sequencing technologies to analyze CRISPR-edited cells enables the identification of edited genomic loci, helping assess the efficiency and specificity of CRISPR-Cas targeting.[8]

Functional Validation Studies

After identifying potential targets, functional validation studies are crucial to confirm the biological relevance of the targeted genes. This often involves additional CRISPR-mediated perturbations, followed by phenotypic and molecular analyses.

In Vivo CRISPR Screens

Expanding CRISPR screens to in vivo models provides a more physiologically relevant context for target identification, bridging the gap between in vitro findings and the complexity of living organisms.

The integration of these diverse methods allows researchers to comprehensively identify and validate target genes, contributing to our understanding of gene function and paving the way for the development of targeted therapies using CRISPR-Cas technology[9]

Therapeutic Development

CRISPR technology has accelerated therapeutic development by facilitating the validation of drug targets and optimizing preclinical models. This section explores how CRISPR is employed in developing disease models, testing drug candidates, and enhancing the efficiency of the drug development pipeline. Case studies of CRISPR applications in the development of targeted therapies are presented.

Challenges and Ethical Considerations

CRISPR-Cas technology has emerged as a revolutionary tool in drug discovery, offering unprecedented capabilities for targeted genome editing and functional genomics. However, this transformative potential is accompanied by a set of challenges and ethical considerations that must be carefully addressed. One prominent challenge is the need for increased precision and reduced off-target effects in the CRISPR editing process, particularly when developing therapies. Ensuring the accuracy of genetic modifications is crucial to avoid unintended consequences and potential side effects in drug candidates. Ethical concerns also arise from the prospect of using CRISPR for enhancement purposes in drug development, raising questions about the ethical boundaries of manipulating genes to enhance performance or treat non-life-threatening conditions.[10]

Additionally, there are concerns related to the equitable distribution of benefits arising from CRISPR applications in drug discovery. The accessibility and affordability of CRISPR technologies may create disparities in the development and availability of novel therapies, potentially exacerbating existing healthcare inequalities. Striking a balance between advancing scientific innovation and ensuring fair access to the benefits of CRISPR-driven drug discovery is a critical ethical consideration.

The use of CRISPR in drug discovery also poses challenges related to unintended consequences in the context of long-term safety and efficacy. Off-target effects or unforeseen interactions between genes may only become apparent in the later stages of clinical trials, emphasizing the importance of thorough preclinical testing and ongoing monitoring.

Moreover, ethical dilemmas arise when considering the potential manipulation of human embryos for drug discovery purposes. The germline editing capabilities of CRISPR raise questions about the ethical permissibility of altering the genetic makeup of future generations, and the implications of such interventions require careful consideration and societal consensus.

As CRISPR technologies progress in drug discovery, a robust ethical framework must be established to guide responsible research practices, prioritize patient safety, and address the broader societal implications. Open communication, engagement with diverse stakeholders, and transparent decision-making processes are essential to navigate these challenges and ensure that CRISPR-based drug discovery aligns with ethical standards and societal values. As the field continues to evolve, a proactive and collaborative approach is paramount to harness the full potential of CRISPR while upholding the principles of ethics and responsible innovation in drug development.[7,8]

Future Perspectives

The paper concludes with a discussion on the future directions of CRISPR technology in drug discovery. Anticipated advancements in CRISPR-based techniques, potential breakthroughs, and areas requiring further research are highlighted. The importance of continued collaboration between researchers, clinicians, and regulatory bodies to harness the full potential of CRISPR in drug discovery is emphasized.[11,12]

In summary, this review paper provides a comprehensive examination of the role of CRISPR technology in drug discovery, showcasing its transformative impact on target identification and therapeutic development. While recognizing the remarkable progress made, the paper also highlights the challenges and ethical considerations that accompany the widespread adoption of CRISPR in the pharmaceutical industry. The insights provided aim to guide researchers and stakeholders in navigating the evolving landscape of CRISPR applications in drug discovery.

References

1. Doudna, Jennifer A., and Samuel H. Sternberg. 2017. A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution. Boston: Houghton Mifflin Harcourt.
2. Jinek, Martin, et al. 2012. “A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity.” Science 337 (6096): 816–21.
3. National Academies of Sciences, Engineering, and Medicine. 2017. Human Genome Editing: Science, Ethics, and Governance. Washington, DC: The National Academies Press.

4. Cong, Le, et al. 2013. “Multiplex Genome Engineering Using CRISPR/Cas Systems.” Science 339 (6121): 819–23.
5. Baltimore, David, et al. 2015. “A Prudent Path Forward for Genomic Engineering and Germline Gene Modification.” Science 348 (6230): 36–38.
6. Hsu, Patrick D., Eric S. Lander, and Feng Zhang. 2014. “Development and Applications of CRISPR-Cas9 for Genome Engineering.” Cell 157 (6): 1262–78.
7. National Institutes of Health. 2020. “Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.” Accessed January 5, 2023. https://osp.od.nih.gov/biotechnology/nih-guidelines/.
8. Charpentier, Emmanuelle, and Jennifer A. Doudna. 2013. “Biotechnology: Rewriting a Genome.” Nature 495 (7439): 50–51.
9. Callaway, Ewen. 2015. “CRISPR Gene-Editing Tested in a Person for the First Time.” Nature News, November 15. https://www.nature.com/news/crispr-gene-editing-tested-in-a-person-for-the-first-time-1.18852.
10. National Institute of Allergy and Infectious Diseases. 2018. “NIH Statement on He Jiankui’s Claim of Gene-Edited Babies in China.” Accessed January 5, 2023. https://www.niaid.nih.gov/news-events/nih-statement-he-jiankuis-claim-gene-edited-babies-china.
11. Ishino, Y., et al. 1987. “Nucleotide Sequence of the Iap Gene, Responsible for Alkaline Phosphatase Isozyme Conversion in Escherichia Coli, and Identification of the Gene Product.” Journal of Bacteriology 169 (12): 5429–33.
12. Berg, Paul, et al. 1974. “Summary Statement of the Asilomar Conference on Recombinant DNA Molecules.” Proceedings of the National Academy of Sciences 71 (12): 4821–23.